<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="CureusCureus2168-8184Cureus2168-8184CureusPalo Alto (CA) pmcid: 7549853 doi: 10.7759/cureus.10357 : Internal Medicine:" exact="Infectious" post="Disease: Pulmonology Overview of the Pathogenesis and Treatment of"/>
 <result pre="a novel coronavirus and was subsequently classified as SARS-CoV-2 (severe" exact="acute" post="respiratory syndrome coronavirus 2) due to similarities in its"/>
 <result pre="novel coronavirus and was subsequently classified as SARS-CoV-2 (severe acute" exact="respiratory" post="syndrome coronavirus 2) due to similarities in its pathogenesis"/>
 <result pre="coronavirus and was subsequently classified as SARS-CoV-2 (severe acute respiratory" exact="syndrome" post="coronavirus 2) due to similarities in its pathogenesis and"/>
 <result pre="in its pathogenesis and conserved replicase sequence with SARS-CoV-1 (severe" exact="acute" post="respiratory syndrome coronavirus 1). Containment measures were initiated; however,"/>
 <result pre="its pathogenesis and conserved replicase sequence with SARS-CoV-1 (severe acute" exact="respiratory" post="syndrome coronavirus 1). Containment measures were initiated; however, the"/>
 <result pre="pathogenesis and conserved replicase sequence with SARS-CoV-1 (severe acute respiratory" exact="syndrome" post="coronavirus 1). Containment measures were initiated; however, the virus"/>
 <result pre="overview of the pathogenesis and treatment of SARS-CoV-2 (COVID-19 [coronavirus" exact="disease" post="2019]) for clinicians. This review includes data on the"/>
 <result pre="these topics. covid19 sars-cov-2 covid induced ards covid-19 management sars-cov-2" exact="infection" post="sars-cov-2 pathogenesis sars-cov-2 induced ards sars-cov-2 treatment remdesivir dexamethasone"/>
 <result pre="immunocompetent people. In fact, coronaviruses account for roughly 10-30% of" exact="upper" post="respiratory infections each yearÂ [1-2]. However, in more recent"/>
 <result pre="people. In fact, coronaviruses account for roughly 10-30% of upper" exact="respiratory" post="infections each yearÂ [1-2]. However, in more recent years"/>
 <result pre="In fact, coronaviruses account for roughly 10-30% of upper respiratory" exact="infections" post="each yearÂ [1-2]. However, in more recent years the"/>
 <result pre="coronavirus family has changed due to the emergence of severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV-1) in 2002 and Middle East"/>
 <result pre="family has changed due to the emergence of severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV-1) in 2002 and Middle East respiratory"/>
 <result pre="has changed due to the emergence of severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV-1) in 2002 and Middle East respiratory syndrome"/>
 <result pre="acute respiratory syndrome coronavirus (SARS-CoV-1) in 2002 and Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) in 2012, both of which led"/>
 <result pre="respiratory syndrome coronavirus (SARS-CoV-1) in 2002 and Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) in 2012, both of which led to"/>
 <result pre="addition, official webpages from the United States, CDC (Centers for" exact="Disease" post="Control and Prevention), NIH (National Institutes of Health), WHO,"/>
 <result pre="articles in the pre-publication process were taken into consideration. A" exact="total" post="of 146 references were collected and analyzed by the"/>
 <result pre="date of publication and impact factor. Pathogenesis Coronaviruses primarily target" exact="epithelial" post="cells and are generally associated with respiratory and gastrointestinal"/>
 <result pre="Coronaviruses primarily target epithelial cells and are generally associated with" exact="respiratory" post="and gastrointestinal infectionsÂ [2,4]. These viruses attach to target"/>
 <result pre="release their genomes into target cells through fusion of the" exact="viral" post="envelope with the host plasma membraneÂ [4]. They utilize"/>
 <result pre="specificitiesÂ [2]. Similarly, SARS-CoV-2 also targets ACE2 receptors on human" exact="respiratory" post="epithelial cells, suggesting a similar RBD structure to SARS-CoV-1Â"/>
 <result pre="[2]. Similarly, SARS-CoV-2 also targets ACE2 receptors on human respiratory" exact="epithelial" post="cells, suggesting a similar RBD structure to SARS-CoV-1Â [5,11]."/>
 <result pre="bind to ACE2 receptors on the surface of human alveolar" exact="epithelial" post="cells. The S protein is divided into two domains,"/>
 <result pre="and furin, localize to virally-target cells.Â (C) These proteases enhance" exact="viral" post="entry into host cells through the proteolysis of both"/>
 <result pre="ACE2 down-regulation). The renin-angiotensin system has a crucial role in" exact="acute" post="lung injury and ACE2 serves a protective role against"/>
 <result pre="secretory proteases are responsible for the cleavage â€œprimingâ€� of various" exact="viral" post="surface receptors and adhesion molecules and thereby enhancing viral"/>
 <result pre="various viral surface receptors and adhesion molecules and thereby enhancing" exact="viral" post="fusion with host cell membranes. In both SARS-CoV-1 and"/>
 <result pre="the S1 and ACE2 proteins, which enhances membrane fusion and" exact="viral" post="uptake (S1 priming and ACE2 downregulation)Â [12-14]. The proteolysis"/>
 <result pre="ACE2 downregulation)Â [12-14]. The proteolysis of ACE2 not only promotes" exact="viral" post="entry but also seems to be a key mechanism"/>
 <result pre="diseaseÂ [10]. The renin-angiotensin system has a crucial role in" exact="acute" post="lung injury in that the ACE2 receptor has a"/>
 <result pre="in that the ACE2 receptor has a protective role against" exact="acute" post="lung failureÂ [10]. ACE2 is therefore a key negative"/>
 <result pre="is therefore a key negative regulatory factor for severity of" exact="lung disease" post="and thus its downregulation contributes to the severity of"/>
 <result pre="therefore a key negative regulatory factor for severity of lung" exact="disease" post="and thus its downregulation contributes to the severity of"/>
 <result pre="efficiently spread throughout the population in comparison to SARS-CoV-1Â [14]." exact="Infection" post="leads to increased levels of cytokines (interferon Î³, interleukin-1,"/>
 <result pre="ferritin)Â [15-17]. This dysregulated host immune response to SARS-CoV-2 lung" exact="infection" post="leading to exuberant cytokine release (cytokine storm) and resultant"/>
 <result pre="postulated as a critical pathogenic factor in the progression to" exact="acute" post="respiratory distress syndrome (ARDS) and other end-organ complicationsÂ [15-17]."/>
 <result pre="as a critical pathogenic factor in the progression to acute" exact="respiratory" post="distress syndrome (ARDS) and other end-organ complicationsÂ [15-17]. ARDS"/>
 <result pre="critical pathogenic factor in the progression to acute respiratory distress" exact="syndrome" post="(ARDS) and other end-organ complicationsÂ [15-17]. ARDS is the"/>
 <result pre="the hallmark immune-mediated clinical consequenceÂ [15]. Other complications include shock," exact="acute" post="kidney injury, acute cardiac injury, liver dysfunction, coagulopathy, infection,"/>
 <result pre="hallmark immune-mediated clinical consequenceÂ [15]. Other complications include shock, acute" exact="kidney injury," post="acute cardiac injury, liver dysfunction, coagulopathy, infection, and even"/>
 <result pre="clinical consequenceÂ [15]. Other complications include shock, acute kidney injury," exact="acute" post="cardiac injury, liver dysfunction, coagulopathy, infection, and even thrombotic"/>
 <result pre="acute cardiac injury, liver dysfunction, coagulopathy, infection, and even thrombotic" exact="disease" post="in otherwise low-risk patientsÂ [17-19]. The proportion of patients"/>
 <result pre="proportionÂ seen among patients labeled with severe SARS-CoV-2Â [17-19]. AKI," exact="acute" post="kidney injury; ARDS, acute respiratory distress syndrome; ICU, intensive"/>
 <result pre="seen among patients labeled with severe SARS-CoV-2Â [17-19]. AKI, acute" exact="kidney injury;" post="ARDS, acute respiratory distress syndrome; ICU, intensive care unit;"/>
 <result pre="labeled with severe SARS-CoV-2Â [17-19]. AKI, acute kidney injury; ARDS," exact="acute" post="respiratory distress syndrome; ICU, intensive care unit; SARS-CoV-2, severe"/>
 <result pre="with severe SARS-CoV-2Â [17-19]. AKI, acute kidney injury; ARDS, acute" exact="respiratory" post="distress syndrome; ICU, intensive care unit; SARS-CoV-2, severe acute"/>
 <result pre="acute respiratory distress syndrome; ICU, intensive care unit; SARS-CoV-2, severe" exact="acute" post="respiratory syndrome coronavirus 2 Â All Lab-Confirmed SARS-CoV-2 Cases"/>
 <result pre="respiratory distress syndrome; ICU, intensive care unit; SARS-CoV-2, severe acute" exact="respiratory" post="syndrome coronavirus 2 Â All Lab-Confirmed SARS-CoV-2 Cases Severe"/>
 <result pre="distress syndrome; ICU, intensive care unit; SARS-CoV-2, severe acute respiratory" exact="syndrome" post="coronavirus 2 Â All Lab-Confirmed SARS-CoV-2 Cases Severe Cases"/>
 <result pre="acute respiratory syndrome coronavirus 2 Â All Lab-Confirmed SARS-CoV-2 Cases" exact="Severe" post="Cases (Higher Risk Patients, ICU Admission) Â Wang et"/>
 <result pre="Â Â Â Â ARDS 20% 3% 61% 16% 69%" exact="Shock" post="9% 1% 31% 6% NA Acute cardiac injury 7%"/>
 <result pre="3% 61% 16% 69% Shock 9% 1% 31% 6% NA" exact="Acute" post="cardiac injury 7% &amp;lt;1% 22% 3% 43% AKI 4%"/>
 <result pre="NA 39% 80% Coagulopathy NA &amp;lt;1% NA &amp;lt;1% 63% Hospital-acquired" exact="infection" post="NA NA NA NA 17% Interestingly, the pediatric population"/>
 <result pre="NA NA 17% Interestingly, the pediatric population is at a" exact="lower" post="risk of severe complications and more likely to be"/>
 <result pre="adults, children reported symptoms such as fever and cough at" exact="lower" post="frequencies and were much less likely to have severe/critical"/>
 <result pre="lower frequencies and were much less likely to have severe/critical" exact="disease" post="(5.9% vs. 18.5%)Â [20-21]. However, when stratified among age"/>
 <result pre="groupÂ [20]. It is hypothesized that children have these milder" exact="pulmonary" post="disease manifestations due to decreased gene expression of ACE2"/>
 <result pre="[20]. It is hypothesized that children have these milder pulmonary" exact="disease" post="manifestations due to decreased gene expression of ACE2 receptors"/>
 <result pre="manifestations due to decreased gene expression of ACE2 receptors on" exact="respiratory" post="epithelial cellsÂ [22]. However, a newly described post-infectious complication"/>
 <result pre="due to decreased gene expression of ACE2 receptors on respiratory" exact="epithelial" post="cellsÂ [22]. However, a newly described post-infectious complication of"/>
 <result pre="newly described post-infectious complication of SARS-CoV-2, known as multisystem inflammatory" exact="syndrome" post="in children (MIS-C), is being reported. This is a"/>
 <result pre="in children (MIS-C), is being reported. This is a Kawasaki-like" exact="syndrome" post="that presents as fever, prominent gastrointestinal upset, rash, conjunctivitis,"/>
 <result pre="not been proven, reports of an increased incidence of Kawasaki-like" exact="syndrome" post="in areas heavily affected by the pandemic show an"/>
 <result pre="should differ from standard ARDS management of patients with other" exact="viral" post="pneumonias. This strategy includes low tidal volume (4-8 mL/kg"/>
 <result pre="a high PEEP in these individuals may subject them to" exact="barotrauma" post="or reduced cardiac outputÂ [25-26]. One study characterized the"/>
 <result pre="â€œtype Hâ€�. â€œType Lâ€� occurs soon after the onset of" exact="respiratory" post="distress and the patientâ€™s lungs retain their normal lung"/>
 <result pre="progression of the patientâ€™s ARDS, resulting in clinical deterioration and" exact="lower" post="lung compliance. Therefore, the study suggests that it may"/>
 <result pre="guidelines recommend that patients on standard oxygen supplementation with refractory" exact="hypoxia" post="should be trialed on high-flow nasal cannula (HFNC) over"/>
 <result pre="stems from the increased risk of aerosol generation and subsequent" exact="viral" post="transmission associated with NIPPV. However, if HFNC is not"/>
 <result pre="examining its efficacy have found improvements in oxygen saturation and" exact="respiratory" post="rates in patients who can adjustÂ their position independently"/>
 <result pre="off supplemental oxygenÂ [24]. SARS-CoV-2 can result in a severe" exact="systemic" post="inflammatory response, which can cause lung injury, ARDS, and"/>
 <result pre="of corticosteroid therapy may help to mitigate or prevent these" exact="viral" post="complications. Corticosteroid use in critically-ill patients suffering from ARDS"/>
 <result pre="use in early ARDS, corticosteroid use for the treatment of" exact="viral" post="infections has been a controversial due to concerns for"/>
 <result pre="in early ARDS, corticosteroid use for the treatment of viral" exact="infections" post="has been a controversial due to concerns for possibly"/>
 <result pre="has been a controversial due to concerns for possibly delayed" exact="viral" post="clearance and subsequent increase in illness duration and poor"/>
 <result pre="with caution as they are preliminaryÂ [37]. Additionally, review of" exact="secondary" post="endpoints, such as need for renal replacement therapy, cardiac"/>
 <result pre="use alternative glucocorticoids, such as prednisone, methylprednisolone, and hydrocortisone. The" exact="total" post="daily dose equivalencies to 6 mg/day of dexamethasone for"/>
 <result pre="Remdesivir is a broad-spectrum antiviral medication that works by targeting" exact="viral" post="RNA polymerase and terminating viral transcription. This medication was"/>
 <result pre="medication that works by targeting viral RNA polymerase and terminating" exact="viral" post="transcription. This medication was first trialed back in January"/>
 <result pre="trial is a multinational, randomized, double-blind, placebo-controlled trial among hospitalized" exact="adult" post="patients with SARS-CoV-2 who had an SpO2 of &amp;lt;94%,"/>
 <result pre="and its analog hydroxychloroquine have historically been used to treat" exact="malaria" post="and certain autoimmune conditions. However, it has been postulated"/>
 <result pre="hydroxychloroquine have historically been used to treat malaria and certain" exact="autoimmune" post="conditions. However, it has been postulated that they may"/>
 <result pre="aloneÂ [45]. Conversely, a potential increased risk of death or" exact="cardiac arrest" post="may be associated with their useÂ [44-45]. Given these"/>
 <result pre="their antibodies to individuals in an effort to suppress the" exact="viral" post="inflammatory response. Several small case-series have reported clinical efficacy"/>
 <result pre="uncommon (&amp;lt;1%), they did include transfusion-associated circulatory overload (TACO), transfusion-related" exact="acute" post="lung injury (TRALI), allergic reactions, and deathÂ [49]. Current"/>
 <result pre="is unlikely that the plasma of donors without confirmed SARS-CoV-2" exact="infection" post="contain high titers of SARS-CoV-2 neutralizing antibodies. Additionally, it"/>
 <result pre="Interferons are not recommended due to their safety concerns and" exact="limited" post="benefit in other coronavirus infectionsÂ [24]. Anticoagulation The incidence"/>
 <result pre="in other coronavirus infectionsÂ [24]. Anticoagulation The incidence of thrombotic" exact="disease" post="in individuals affected by SARS-CoV-2 is reported as high"/>
 <result pre="adults with SARS-CoV-2 should receive the same prophylaxis against arterial" exact="thrombosis" post="or venous thromboembolism as per the SOC of other"/>
 <result pre="SARS-CoV-2 should receive the same prophylaxis against arterial thrombosis or" exact="venous thromboembolism" post="as per the SOC of other hospitalized individuals. Patients"/>
 <result pre="retrospective analysis of 2,773 patients treated either with or without" exact="systemic" post="anticoagulation found no difference in overall mortality among the"/>
 <result pre="need for future prospective clinical trials. Concomitant Therapies Patients receiving" exact="chronic" post="anticoagulation/platelet therapies should continue these medications after a SARS-CoV-2"/>
 <result pre="inhibitors, angiotensin receptor blockers, and HMG-CoA reductase inhibitors for certain" exact="chronic" post="conditions prior to a diagnosis of SARS-CoV-2 should not"/>
 <result pre="should not discontinue their therapyÂ [24]. Patients also taking either" exact="chronic" post="oral or inhaled steroids should also continue with therapy"/>
 <result pre="state of knowledge on these topics. Patients with persistent hypoxemic" exact="respiratory" post="failure on conventional oxygen supplementation should be treated with"/>
 <result pre="BiPAP) are acceptable strategies to treat SARS-CoV-2 for short-term life-threatening" exact="respiratory" post="conditions if HFNC is unavailable and there is no"/>
 <result pre="to have a greater benefit in patients with more severe" exact="pulmonary" post="disease (in need of supplemental oxygen), whereas remdesivir seems"/>
 <result pre="have a greater benefit in patients with more severe pulmonary" exact="disease" post="(in need of supplemental oxygen), whereas remdesivir seems to"/>
 <result pre="have declared that no competing interests exist. References References 1Coronavirus" exact="infections" post="- more than just the common coldJAMAPaulesCMarstonHFauciA707708323202031971553 2Origin and"/>
 <result pre="for risk of human transmissionSci China Life SciXuXChenPWangJet al.45746063202032009228 6A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 <result pre="al.271280181202032142651 12A transmembrane serine protease is linked to the severe" exact="acute" post="respiratory syndrome coronavirus receptor and activates virus entryJ VirolShullaAHeald-SargentTSubramanyaGZhaoJPerlmanSGallagherT87388285201121068237"/>
 <result pre="12A transmembrane serine protease is linked to the severe acute" exact="respiratory" post="syndrome coronavirus receptor and activates virus entryJ VirolShullaAHeald-SargentTSubramanyaGZhaoJPerlmanSGallagherT87388285201121068237 13TMPRSS2"/>
 <result pre="transmembrane serine protease is linked to the severe acute respiratory" exact="syndrome" post="coronavirus receptor and activates virus entryJ VirolShullaAHeald-SargentTSubramanyaGZhaoJPerlmanSGallagherT87388285201121068237 13TMPRSS2 and"/>
 <result pre="only proteolysis by TMPRSS2 augments entry driven by the severe" exact="acute" post="respiratory syndrome coronavirus spike proteinJ VirolHeurichAHofmann-WinklerHGiererSLiepoldTJahnOPohlmannS1293130788201424227843 14The spike glycoprotein"/>
 <result pre="proteolysis by TMPRSS2 augments entry driven by the severe acute" exact="respiratory" post="syndrome coronavirus spike proteinJ VirolHeurichAHofmann-WinklerHGiererSLiepoldTJahnOPohlmannS1293130788201424227843 14The spike glycoprotein of"/>
 <result pre="by TMPRSS2 augments entry driven by the severe acute respiratory" exact="syndrome" post="coronavirus spike proteinJ VirolHeurichAHofmann-WinklerHGiererSLiepoldTJahnOPohlmannS1293130788201424227843 14The spike glycoprotein of the"/>
 <result pre="involvement of the chemokine/chemokine-receptor systemCytokine Growth Factor RevCoperchiniFChiovatoLCroceLMagriFRotondiM253253202032446778 16Cytokine release" exact="syndrome" post="in severe COVID- 19: interleukin-6 receptor antagonist tocilizumab may"/>
 <result pre="to reduce mortalityInt J Antimicrob AgentsZhangCWuZLiJWZhaoHWangGQ15552020 17Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN Engl J MedGuanWJNiZYHuYet al.17081720382202032109013 18Clinical characteristics"/>
 <result pre="18Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, ChinaJAMAWangDHuBHuCet al.10611069323202032031570 19Clinical course and predictors of"/>
 <result pre="a systematic review and meta-analysisJ Formos Med AssocChangTHWuJLChangLY982989119202032307322 22Multi-system inflammatory" exact="syndrome" post="in children (MIS-C) following SARS-CoV-2 infection: review of clinical"/>
 <result pre="pathogenesis, and proposed managementChildren (Basel)NakraNBlumbergDHerrera-GuerraALakshminrusimhaS6972020 23An outbreak of severe Kawasaki-like" exact="disease" post="at the Italian epicentre of the SARS-CoV-2 epidemic: an"/>
 <result pre="of the SARS-CoV-2 epidemic: an observational cohort studyLancetVerdoniLMazzaAGervasoniAet al.17711778395202032410760 24Coronavirus" exact="Disease" post="2019 (COVID-19) Treatment Guidelines820202020https://www.covid19treatmentguidelines.nih.gov/ 25Management of COVID-19 respiratory distressJAMAMariniJJGattinoniL23292330323202032329799"/>
 <result pre="al.17711778395202032410760 24Coronavirus Disease 2019 (COVID-19) Treatment Guidelines820202020https://www.covid19treatmentguidelines.nih.gov/ 25Management of COVID-19" exact="respiratory" post="distressJAMAMariniJJGattinoniL23292330323202032329799 26PEEP levels in COVID-19 pneumoniaCrit CareTsolakiVSiemposIMagiraEKokkorisSZakynthinosGEZakynthinosS30324202032505186 27Surviving Sepsis"/>
 <result pre="guidelines on the management of critically ill adults with coronavirus" exact="disease" post="2019 (COVID-19)Crit Care MedAlhazzaniWMollerMHArabiYMet al.44046948202032058385 28Noninvasive ventilation in acute"/>
 <result pre="coronavirus disease 2019 (COVID-19)Crit Care MedAlhazzaniWMollerMHArabiYMet al.44046948202032058385 28Noninvasive ventilation in" exact="acute" post="hypoxemic nonhypercapnic respiratory failure: a systematic review and meta-analysisCrit"/>
 <result pre="(COVID-19)Crit Care MedAlhazzaniWMollerMHArabiYMet al.44046948202032058385 28Noninvasive ventilation in acute hypoxemic nonhypercapnic" exact="respiratory" post="failure: a systematic review and meta-analysisCrit Care MedXuXPZhangXCHuSLet al.727733452017"/>
 <result pre="review and meta-analysisCrit Care MedXuXPZhangXCHuSLet al.727733452017 29Prone positioning in severe" exact="acute" post="respiratory distress syndromeN Engl J MedGuerinCReignierJRichardJCet al.21592168368201323688302 30Early self-proning"/>
 <result pre="and meta-analysisCrit Care MedXuXPZhangXCHuSLet al.727733452017 29Prone positioning in severe acute" exact="respiratory" post="distress syndromeN Engl J MedGuerinCReignierJRichardJCet al.21592168368201323688302 30Early self-proning in"/>
 <result pre="controlled trialChestMeduriGUGoldenEFreireAXet al.954963131200717426195 33Efficacy and safety of corticosteroids for persistent" exact="acute" post="respiratory distress syndromeN Engl J MedSteinbergKPHudsonLDGoodmanRBet al.16711684354200616625008 34Dexamethasone treatment"/>
 <result pre="trialChestMeduriGUGoldenEFreireAXet al.954963131200717426195 33Efficacy and safety of corticosteroids for persistent acute" exact="respiratory" post="distress syndromeN Engl J MedSteinbergKPHudsonLDGoodmanRBet al.16711684354200616625008 34Dexamethasone treatment for"/>
 <result pre="distress syndromeN Engl J MedSteinbergKPHudsonLDGoodmanRBet al.16711684354200616625008 34Dexamethasone treatment for the" exact="acute" post="respiratory distress syndrome: a multicentre, randomised controlled trialLancet Respir"/>
 <result pre="syndromeN Engl J MedSteinbergKPHudsonLDGoodmanRBet al.16711684354200616625008 34Dexamethasone treatment for the acute" exact="respiratory" post="distress syndrome: a multicentre, randomised controlled trialLancet Respir MedVillarJFerrandoCMartinezDet"/>
 <result pre="syndrome: a multicentre, randomised controlled trialLancet Respir MedVillarJFerrandoCMartinezDet al.2672768202032043986 35Early" exact="short" post="course corticosteroids in hospitalized patients with COVID-19 [Online ahead"/>
 <result pre="chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical"/>
 <result pre="diphosphate as adjunctive therapy for patients hospitalized with severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trialJAMA"/>
 <result pre="as adjunctive therapy for patients hospitalized with severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trialJAMA Netw"/>
</results>
